ProMining hopes to hit rich seam with Spark

Cresset, a provider of chemistry software and services, has chosen ProMining Therapeutics to license SparkV10 for assistance in its hit-to-lead optimisation efforts. SparkV10 is Cresset’s desktop bioisostere software tool, which is used by medicinal and computational chemists for drug design.

Dr David Bardsley, Cresset’s sales director, said: 'SparkV10 is an exciting and powerful way of generating novel and diverse structures. We are delighted that ProMining, an early-stage biopharmaceutical research and development company, has chosen to work with sparkV10 for the development of small molecule drugs.'

ProMining Therapeutics' CTO Dr Boaz Inbal, added: 'We are excited about using SparkV10 in our oncology project. We believe SparkV10 will guide us through several optimisation challenges.

'As a result, we will be able to better understand the behaviour of several chemical groups in the context of our hit scaffold and to test some required replacement hypotheses.'

Twitter icon
Google icon icon
Digg icon
LinkedIn icon
Reddit icon
e-mail icon
Analysis and opinion

Robert Roe looks at research from the University of Alaska that is using HPC to change the way we look at the movement of ice sheets


Robert Roe talks to cooling experts to find out what innovation lies ahead for HPC users

Analysis and opinion